Europe Chronic Pain Market

Europe Chronic Pain Market Size (2023 to 2028)

The chronic pain market size in Europe is anticipated to be worth USD 29.92 billion by 2028 from USD 23.13 billion in 2023, growing at a CAGR of 5.29% from 2023 to 2028.

The growing geriatric population in the European region primarily drives the growth of the European chronic pain market. As per statistics published by Eurostat, an estimated 21.1% of the European population aged above 65 years in 2022. People who are aged are more likely to experience a range of chronic pain conditions, including headaches, body pain, cancer pain, arthritis, neuropathic pain and others. Moreover, work-related stress often leads to back pain complaints among the European population.

The growing number of surgeries being performed in the European region on a regular basis further contributes to the European chronic pain market growth. Factors such as road accidents, chronic diseases and injuries contribute to the growing demand for surgical procedures, often resulting in severe pain at the site of operation. Individuals undergoing surgeries prefer doctor-prescribed medications and devices to alleviate chronic pain. Furthermore, individuals working in the industrial sector are more susceptible to chronic pain.

The growing R&D efforts to manufacture effective devices and medications for chronic pain fuels the growth rate of the European chronic pain market. Researchers are dedicated to advancing technologies and utilizing sensors to develop devices that effectively alleviate pain. Factors such as increased research and development, product approvals, support from pharmaceutical and medical device companies and government backing further drive European market growth.

The growing number of advancements in pain management technologies and devices, rising awareness and understanding of chronic pain management among healthcare professionals and patients and supportive government initiatives and policies promoting access to pain management therapies in Europe promote the European chronic pain market growth. The growing number of collaborations and partnerships between pharmaceutical and medical device companies to develop innovative solutions and rising emphasis focus on improving the quality of life for patients with chronic pain through multidisciplinary approaches further boost the growth rate of the European market.

Stringent regulatory requirements and challenges in gaining approvals for new pain management medications and devices, limited reimbursement coverage for certain chronic pain treatments and high costs associated with innovative pain management technologies and medications majorly hamper the growth of the European chronic pain market. Poor awareness and understanding of chronic pain management among healthcare professionals and patients, stigma and misconceptions surrounding chronic pain, limited availability of specialized pain management clinics and healthcare providers and adverse side effects associated with certain pain medications further hinder the European market growth.

This research report on the Europe chronic pain market has been segmented and sub-segmented into the following categories.

By Indication:

• Neuropathic pain
• Chronic back pain
• Arthritis pain
• Migraine
• Cancer pain
• Fibromyalgia
• Others

By Product:

• Drugs
• Devices

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The European region held a notable share of the global market in 2022 and is predicted to continue to hold a substantial share of the worldwide market during the forecast period owing to the increasing accessibility to advanced healthcare technologies and increased healthcare expenditure. Approximately 100 million people in Europe suffer from chronic pain. The governments of European countries have implemented measures to approve innovative pain management products and drugs, while the growing presence of pharmaceutical companies further fuels market expansion. Increased awareness campaigns by healthcare organizations and manufacturers about pain management devices and equipment, and advertising through social media and television platforms enhance the European market growth.

Germany had the largest share of the European market in 2022 and is estimated to grow at a healthy CAGR during the forecast period owing to the growing number of manufacturing facilities. The increasing health consciousness among individuals has resulted in a focus on fitness and gym workouts, leading to the use of stress-reducing medications and supporting the German market growth. In Germany, some healthcare providers prefer Cannabis for chronic pain management, gradually alleviating pain.

The UK chronic pain market is anticipated to showcase a noteworthy CAGR during the forecast period due to the growing number of clinical trial centers. Additionally, the increasing availability of training centers to educate healthcare professionals about pain management devices further facilitates the UK market growth.

KEY MARKET PARTICIPANTS:

Pfizer Inc., Novartis International AG, Johnson & Johnson, Grünenthal Group and Eli Lilly and Company are some of the notable players in the European chronic pain market and are profiled in this report.